BREAKING: Key GOP U.S. Senator Presses HHS Deputy Secretary Nominee to Take Action on 340B

Andrea Palm, President Biden's pick to be HHS Deputy Secretary, indicated in response to a question during her confirmation hearing today that "there are things [HHS] can and needs to be doing" about 340B hospitals' complaints about drugs manufacturers and PBMs.

Andrea Palm, President Biden’s pick to be the number two official at the U.S. Health and Human Services Department (HHS), pledged during her U.S. Senate confirmation hearing this morning to make sure that the 340B program “is working as it

Read More »

Could Concern About Hospital Price Transparency Boost Push for More Hospital 340B Transparency?

Bipartisan concern in Congress about hospitals' compliance with new price transparency rules might enhearten drugmakers and others who want to impose reporting requirements on 340B hospitals. | Shutterstock

The bipartisan leaders of the U.S. House Energy and Commerce (E&C) Committee and its Health Subcommittee wrote to U.S. Health and Human Services (HHS) Secretary Xavier Becerra this week asking him to enforce “full compliance” with the Trump administration’s hospital

Read More »

Historic U.S. Rise in STDs Boosts 340B’s Importance, STD Program Directors Say

340B drug discount savings help STD clinics and grantees expand access to quality and affordable sexual health care, the National Coalition of STD Directors (NCSD) says. | Shutterstock

News this week that sexually transmitted disease (STD) reported cases in the U.S. reached all-time highs for the sixth straight year shows why STD clinic access to 340B drug discounts is vital, state and local STD program directors say.

New

Read More »

340B Report Publisher and CEO Slafsky: Providers Need Swift Action on Contract Pharmacy

With Xavier Becerra in place as HHS secretary, 340B providers are hopeful he will act fast and decisively against drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting. | Shutterstock

340B health care providers are hopeful that U.S. health secretary Xavier Becerra will sanction six drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting, 340B Report Publisher and CEO

Read More »

340B Could Come Up During Congressional Hearings Thursday

From left to right, HHS Secretary Xavier Becerra, CMS Administrator nominee Chiquita Brooks-LaSure, and HHS Deputy Secretary nominee Andrea Palm will all be on Capitol Hill on Thursday.

The U.S. Senate Finance Committee is scheduled to hold a hearing Thursday morning on President Biden’s nominations of Chiquita Brooks-LaSure to run the U.S. Centers for Medicare & Medicaid Services, and Andrea Palm to be U.S. Health and Human Services

Read More »

MACPAC Backs Medicaid Change That Could Lower Some 340B Prices

Raising the Medicaid rebate percentage and inflation penalty on accelerated-approval drugs, as the Medicaid and CHIP Payment and Access Commission (MACPAC) recommends, could lead to lower 340B ceiling prices on those drugs.

Congressional Medicaid policy advisers voted Friday to recommend raising the Medicaid rebate percentage and inflation penalty on drugs that are quickly and conditionally approved to treat serious conditions that fill an unmet need.

If Congress follows the Medicaid and CHIP

Read More »

340B Entities Won’t Share in BMS’s $75 Million Medicaid Drug Pricing Settlement

A whistleblower alleged that Bristol-Myers Squibb misreported prices on more than 200 drug products, reducing Medicaid rebates it owed to states.

340B covered entities were not included in Bristol-Myers Squibb’s $75 million settlement last week of a whistleblower’s claims that BMS “falsely reported improperly reduced average manufacturer prices” (AMPs) on multiple drugs from October 2007 through March 2016.

Ronald Streck, former

Read More »

AHA Warns MedPAC its Recommendations Would Harm 340B Hospitals

Hospitals say that Medicare Part B drug reimbursement changes that MedPAC endorsed last week would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018. | Shutterstock

Congressional Medicare policy advisers on Friday unanimously endorsed Medicare Part B drug reimbursement changes that hospitals say would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018.

The Medicare Payment Advisory Commission (MedPAC)

Read More »

Panelists Share Insights on Using 340B in Prisons and Jails

Correctional institutions can maximize their funds and improve inmate care by partnering with or becoming 340B covered entities, but doing so can be tricky, experts said during a March 31 webinar. | Shutterstock

Prisons struggling with the high cost of treating inmates with viral illnesses such as hepatitis C and HIV can turn to the 340B program for relief, but participation is often tricky.

That was the takeaway of “Demystifying 340B for Correctional

Read More »

HHS’s Latest Regulatory Agenda Is Silent on 340B, but Program Rulemaking Is Possible

HHS's latest semi-annual regulatory agenda is mum on 340B, but that doesn't mean there is nothing 340B-related in the pipeline. | Shutterstock

The U.S. Health and Human Services Department (HHS) yesterday released the spring edition of its twice-annual public inventory of forthcoming regulatory actions. Although it was silent about the 340B program, 340B stakeholders shouldn’t breathe a sigh of relief yet.

Just

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report